Page 103 - Sohini Das

Jio PAT beats Street estimates, up 65% y-o-y on robust user addition

RIL reiterated plans to hive off the fibre and tower businesses into separate companies to manage spend on these capex heavy business segments

Biocon likely to channelise investments towards non-insulin biologics

Globally, the insulin business has come under pressure

Indian pharma industry records 9.4% growth in 2018, dispels GST gloom

The industry performed better in 2018, in comparison, on a GST-impacted low base

Reliance Jio may capture 51% revenue market share in 3 years: Analysts

Airtel and Vodafone Idea are also trying to expand the penetration of fourth-generation technology (4G) users in their subscriber base as they take this network to the hinterland

DPCO amendment may benefit MNC device makers by allowing price control

Local industry fears global firms will register equipment as 'innovative' to secure price control waiver for 5 years

Natco Pharma shifts focus from US, to spend 70% funds in emerging markets

60-70% of the R&D spend will be for developing portfolio in Brazil, Canada, China & India

Reliance Jio to hive off fibre, tower businesses into separate companies

An analyst pointed out that of the Rs 4 trillion investment announced by Reliance Jio, about Rs 1.2 trillion is estimated to be for the fibre business

Reliance Jio continues to boost subscriber base in metros, Airtel hangs on

Reliance Jio is also banking on GigaFiber to get more subscribers in the metros

Pharma margins to get rupee boost in Q2, highlights report

This would also safeguard them from margin pressure, said the report

Avenue Supermarts' Q2 net profit up 18.3% at Rs 2.26 billion YoY

The company added three stores during the quarter

USFDA drug approvals at all-time high; Indian firms get 35-40% of nods

The regulator has bettered last year's numbers with 971 approval actions this year

After strong Q1, drug firms' revenue growth to dip to 7%, say analysts

The first quarter (Q1) of this financial year was a strong one for pharmaceutical players, driven by 28 per cent domestic growth on a GST-disrupted base

India's first REIT is here: Embassy Office Parks proposes to raise Rs 52 bn

The joint venture of Blackstone and Embassy Group eyes Rs 52 bn through listing of 33 mn sq ft of office space

Oxytocin ban: Sole producer KAPL struggles with excess capacity, inventory

The firm had capacity to produce five million ampoules of oxytocin in a month; it is in the process of adding another 5.1 million ampoules a month of capacity by October 15, says MD Nirja Saraf

Shivinder Singh snaps ties with brother Malvinder, drags him to NCLT

Accuses Malvinder and Godhwani of oppression and mismanagement of group firms

J&J faulty hip implant case: Govt asks all states to form committees

The government has accepted the proposal but has decided to form state-level committees

Abbott India ups vaccines play, to launch products in infant segment

According to analysts, AIL's presence in the high-margin vaccine segment is likely to drive its future growth

After Fortis race, Manipal plots growth in India, overseas markets

Rough estimates show that at a rate of Rs 10 million per hospital bed, the investment in India alone would be around Rs 20 billion

Aurobindo pharma likely to clinch Mallinckrodt deal for $800 mn this July

Street is cautious as Mallinckrodt biz is declining amid enhanced scrutiny on opioid drugs

Indian companies giving MNCs a run for their money in vitamins

Three of top five pharmaceutical companies by market share based in India